Neuroimaging dopamine networks and antidepressant response to Pramipexole in persons with HIV: The COPE Mechanism Study
About This Grant
Project Summary This investigation will conduct a ancillary neuroimaging study of a subgroup of participants (N=48) of a larger clinical trial (N=186) comparing a dopamine agonist (Pramipexole) vs. an SSRI (Escitalopram) for antidepressant efficacy in Major Depressive Disorder in persons with HIV. The neuroimaging study will investigate dopaminergic mechanisms underlying Major Depressive Disorder in persons with HIV infection (Aim 1) and in antidepressant treatment response (Aims 2). Participants of the imaging substudy will undergo FDA approved SPECT/CT imaging for analysis of striatal (caudate, putamen) dopamine transporter (DaT) levels. Multiparametric MRI will be used to interrogate striatal, midbrain regions (caudate, putamen, substantia nigra, and ventral tegmentum) and specific networks (Salience, Somatomotor, Default Mode, and Central/Frontal Executive). Research Domain Criteria will be used to evaluate specific symptoms of depression. We will test the hypothesis that striatal dopaminergic levels are reduced in both groups prior to treatment and correlate with severity of RDoC measures and brain alterations quantified with MRI (Aim 1). We hypothesize that pramipexole, as a dopamine agonist, will reverse decrements in DA transmission to a greater extent than Escitalopram following 24 weeks of treatment. The pramipexole group will show greater remission in symptoms and this change will correlate with changes in DaT levels and in brain imaging measures (Aim 2). This study will yield critical insights concerning dopaminergic mechanisms underlying the markedly higher risk of depression in persons with HIV and have broad relevance to an understanding of MDD which impacts 264 million persons worldwide.
Grant Summary
Neuroimaging dopamine networks and antidepressant response to Pramipexole in persons with HIV: The COPE Mechanism Study is a NIMH - National Institute of Mental Health grant providing up to $715K for university, nonprofit, healthcare org. Applications are due 2031-06-30 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $715K
2031-06-30
- 1Confirm your organization is eligible for Neuroimaging dopamine networks and antidepressant response to Pramipexole in persons with HIV: The COPE Mechanism Study from NIMH - National Institute of Mental Health, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIMH - National Institute of Mental Health before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIMH - National Institute of Mental Health's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Neuroimaging dopamine networks and antidepressant response to Pramipexole in persons with HIV: The COPE Mechanism Study: Frequently Asked Questions
Who is eligible for the Neuroimaging dopamine networks and antidepressant response to Pramipexole in persons with HIV: The COPE Mechanism Study?
Neuroimaging dopamine networks and antidepressant response to Pramipexole in persons with HIV: The COPE Mechanism Study is offered by NIMH - National Institute of Mental Health and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Neuroimaging dopamine networks and antidepressant response to Pramipexole in persons with HIV: The COPE Mechanism Study provide?
Neuroimaging dopamine networks and antidepressant response to Pramipexole in persons with HIV: The COPE Mechanism Study provides up to $715K per award from NIMH - National Institute of Mental Health. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Neuroimaging dopamine networks and antidepressant response to Pramipexole in persons with HIV: The COPE Mechanism Study deadline?
Applications for Neuroimaging dopamine networks and antidepressant response to Pramipexole in persons with HIV: The COPE Mechanism Study are due 2031-06-30 (open). Because deadlines can change, verify the date with the funder, NIMH - National Institute of Mental Health, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Neuroimaging dopamine networks and antidepressant response to Pramipexole in persons with HIV: The COPE Mechanism Study?
To apply for Neuroimaging dopamine networks and antidepressant response to Pramipexole in persons with HIV: The COPE Mechanism Study, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIMH - National Institute of Mental Health.